Saturday, October 31, 2026

Aurora Cannabis Soars 23% At Opening Bell On Monday, Outshines Market

ViaNews Editorial Team

September 11, 2023

Aurora Cannabis Soars 23% At Opening Bell On Monday, Outshines Market

(VIANEWS) - Aurora Cannabis (NYSE: ACB) shares experienced an astonishing 23.84% surge to EUR0.66 at 10:02 EST on Monday morning, continuing the upward trend seen over recent sessions. At 10:02 EST the wider market followed suit and gained 0.09% to EUR15,878.99; suggesting a bullish trading session both for Aurora Cannabis and overall.

About Aurora Cannabis

Aurora Cannabis, based out of Canada, specializes in producing, distributing, and selling cannabis-related products in both Canada and internationally. Aurora operates through three segments: Canadian Cannabis, European Cannabis, and Plant Propagation. The company cultivates and sells medical and recreational cannabis products such as dried flowers, oils, capsules, edibles and extracts; provides patient counseling services; as well as offers patient outreach programs. Additionally, it offers wholesale medical cannabis distribution across Europe, Australia, South America and Israel as well as propagated vegetables and ornamental plants in North America. Aurora Cannabis offers adult-use brands including Aurora Drift, San Rafael '71 Daily Special Whistler Being Greybeard CBD Reliva and KG7 Reliva as well as medical cannabis brands like MedReleaf CanniMed Aurora Whistler Medical Marijuana Co Pedanios Bidiol CraftPlant MedReleaf MedReleaf CanniMed CanniMed Aurora Whistler Being and Greybeard from their adult-use product lineup. Aurora Cannabis' headquarters are in Leduc, Canada

Technical Analysis

Aurora Cannabis stock price has been classified as oversold according to the stochastic oscillator, a popular technical indicator that measures momentum of price movements in stocks. This indicates that Aurora may be undervalued and due for a price rebound. Last reported volume for this stock was 21,885,690 - representing an increase of 331.31% compared to its average volume of 5,074,220. Such high trading volume could indicate increased investor enthusiasm and contribute towards price restoration in the near future. Stock prices are determined by many different variables, including market trends, company news and performance as well as overall economic conditions. Therefore, investors should conduct thorough research before making investment decisions; those interested in Aurora Cannabis might consider doing this due to its oversold classification and high trading volume presenting potential gains.

Equity Analysis

Aurora Cannabis, a Canadian company, reported an earnings per share (EPS) value of EUR-6.5 for their trailing twelve month earnings period ending September 2017. An earnings per share measurement provides insight into a company's profitability on an individual share level; negative values indicate losses, such as in Aurora Cannabis' case wherein their recent performance has been unprofitable. Notably, cannabis industry companies may experience substantial fluctuations in their financial results as they adapt to regulatory hurdles, competition and market dynamics. Investors assessing Aurora Cannabis should take several factors into account when assessing its investment potential, including financial position, growth prospects, competitive advantages, and overall market trends. Before making any definitive investment decisions it is vital to conduct thorough research and seek expert advice.

More news about Aurora Cannabis (ACB).

ViaNews Editorial Team

Via News Editorial Team delivers comprehensive financial news coverage and market analysis from journalists around the world. Our team specializes in data journalism and in-depth reporting on stock markets, business developments, and economic trends.

What we know · the intelligence behind this page
Live from the substrate
What we're seeing
ESMO 2026 Oncology Catalyst Cluster: Ivonescimab's PDUFA Date and Small-Cap Biotech Delistings
ESMO 2026 (Oct 22-24) concentrates a wave of oncology readouts. Summit's ivonescimab (10 presentations, positive HARMONi-GI1 OS, new EA2251 Phase II/III with ECOG-ACRIN) leads, ahead of its FDA PDUFA date of 2026-11-14, and Daiichi Sankyo's DXd ADC platform (REJOICE-Ovarian, DESTINY-Lung04, TUXEDO-3) follows. At the other end of the capital-markets spectrum, micro-cap Spago Nanomedical is moving to delist from Nasdaq First North (board resolution Oct 22, EGM Nov 19, application Jan 2027). Pivotal data and regulatory milestones are rewarding well-funded late-stage players, while cash-constrained early-stage developers are exiting public markets.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,995
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,995 facts checked against source5,525 source documents archived
Query this data → isubstrate.com